Articles from Ferring Pharmaceuticals

Ferring Pharmaceuticals announced today additional evidence from the real-world experience of a private urology practice assessing the efficacy and safety of ADSTILADRIN® (nadofaragene firadenovec-vncg) in patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1).

Ferring Pharmaceuticals is honored to recognize World IVF Day by amplifying the voices of those who have experienced the emotional and often unseen challenges of navigating infertility. TV personality Jessel Taank, Olympic gold medalist Tara Lipinski and leading reproductive endocrinologist Dr. Lucky Sekhon are sharing their personal stories and first-hand perspectives to help normalize the conversation around infertility. Together, they are spotlighting Fertility Out Loud, a digital platform and social community made possible by Ferring. Created to meet the diverse needs of aspiring parents, Fertility Out Loud offers personal stories, expert insights, and helpful resources to empower them at every step toward building their family.

Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ovarian stimulation in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) gonadotrophin-releasing hormone (GnRH) antagonist protocol cycles. This is the key finding of a trial presented today at the European Society of Human Reproduction and Embryology (ESHRE) Congress in Paris and published in Human Reproduction. These data build on previous studies which have established an estimated point of clinical correspondence for 10 µg follitropin delta to 150 IU follitropin alfa in this class of medications.1,2

Ferring Pharmaceuticals presented initial findings from the investigational Phase 3b multi-center, single-arm CDI-SCOPE study evaluating the safety and effectiveness of REBYOTA® (fecal microbiota, live – jslm) when administered by colonoscopy. REBYOTA is the first microbiome-based therapy approved for the prevention of recurrent Clostridioides difficile (C. diff) infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for C. diff infection. These data were presented at Digestive Disease Week 2025 (DDW2025) from May 3-6 in San Diego, CA.

Ferring Pharmaceuticals announced today the U.S. Food and Drug Administration (FDA) approved a state-of-the-art drug product manufacturing hub in Parsippany, NJ, for its intravesical non-replicating gene therapy ADSTILADRIN® (nadofaragene firadenovec-vncg). The approval expands Ferring’s manufacturing capabilities to three cutting-edge sites dedicated to bringing ADSTILADRIN to patients and secures a final $200 million payment from Royalty Pharma (Nasdaq: RPRX) as part of a royalty-based financing agreement announced in 2023.

Ferring Pharmaceuticals presented the initial results from an ongoing Phase 3 trial (NCT05704244) in Japan assessing the efficacy and safety of ADSTILADRIN® (nadofaragene firadenovec-vncg) in patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1).1 ADSTILADRIN is the first and only intravesical non-replicating gene therapy approved by the U.S. Food and Drug Administration (FDA) in this patient population. ADSTILADRIN is not approved for use in Japan.

Ferring achieved total revenues of €2.3 billion in 2024, an increase of 7% over the previous year at actual exchange rates (AER) and 8% at constant exchange rates (CER). This above market growth reflected the continued strong performance in Reproductive Medicine, which exceeded €1 billion in global sales for the first time. In addition, 2024 was the first full year of U.S. sales of Adstiladrin, our novel gene-based therapy for bladder cancer.

Ferring Pharmaceuticals announced today three abstracts featuring ADSTILADRIN® (nadofaragene firadenovec-vncg) will be presented at the 2025 American Society of Clinical Oncologists Genitourinary Cancers (ASCO GU) Symposium held February 13-15 in San Francisco. ADSTILADRIN is the first and only intravesical non-replicating gene therapy approved by the U.S. Food and Drug Administration (FDA) for patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1).

Ferring Pharmaceuticals is celebrating the second anniversary of the launch of REBYOTA® (fecal microbiota, live – jslm), the first microbiome-based therapy approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent C. difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for C. diff infection.

Ferring Pharmaceuticals today announced it has advanced three studies in the ADSTILADRIN® (nadofaragene firadenovec-vncg) clinical trial program – two studies in patients with non-muscle invasive bladder cancer (NMIBC), and one study in patients with upper tract urothelial cancer (UTUC). The Company also announced researchers will present at the 25th Annual Meeting of the Society of Urologic Oncology (SUO) the study protocol for patients with intermediate-risk NMIBC and additional data from a Phase 3, open-label study demonstrating clinically meaningful cystectomy-free survival (CFS) after five years among patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC who achieved an initial complete response at three months with ADSTILADRIN.

Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced that the Anesthetic and Analgesic Drug Products Advisory Committee of the U.S. Food and Drug Administration (FDA) will hold a meeting on January 10, 2025, to review data supporting the biologics license application (BLA) for SI-6603 (generic name: condoliase), an investigational product being studied for the treatment of radicular leg pain associated with lumbar disc herniation (LDH) in adults.

Ferring Pharmaceuticals today announced three poster presentations at the American College of Gastroenterology’s annual meeting (ACG 2024), including two analyses evaluating the efficacy and safety of REBYOTA® (fecal microbiota, live – jslm) administered in a real-world setting and an interim analysis looking at health-related quality of life among REBYOTA patients. REBYOTA is the first and only single-dose microbiome-based therapy approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent C. difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for C. diff infection.

Ferring Pharmaceuticals will present new data from four abstracts at the upcoming 2024 American Society for Reproductive Medicine (ASRM) Congress, being held October 19-23 in Denver, Colorado, and virtually.

Ferring Pharmaceuticals today announced the presentation of two data analyses at IDWeek 2024 evaluating the efficacy and safety of REBYOTA® (fecal microbiota, live – jslm) administered in a real-world setting. REBYOTA is the first and only single-dose microbiome-based therapy approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent C. difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for C. diff infection.

Ferring Pharmaceuticals today announced the opening of a state-of-the-art global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin® (nadofaragene firadenovec-vncg). This represents a significant milestone in Ferring’s capabilities and capacity to meet the current and expected growth in demand for this gene therapy for people with non-muscle invasive bladder cancer (NMIBC).

Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) in patients with mild-to-moderate ulcerative colitis (M2M UC). These results have been published in the Journal of Clinical Medicine.1

Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced the presentation of data from two Phase 3 trials evaluating the efficacy and safety of SI-6603 (generic name: condoliase), an investigational product being studied for the treatment of radicular leg pain associated with lumbar disc herniation (LDH). The podium presentation at the North American Spine Society’s (NASS) Annual Meeting included results from one study conducted in the U.S. and one in Japan. In addition, The Spine Journal has published the results of the pivotal U.S. Phase 3 study.

Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced they will be presenting an analysis of data at the North American Spine Society’s (NASS) Annual Meeting from two Phase 3 trials for SI-6603, an investigational product being studied for the treatment of radicular leg pain associated with lumbar disc herniation (LDH). The congress will take place September 25-28, 2024, in Chicago, IL.

Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced the presentation of a Phase 3 data analysis evaluating the early treatment response to SI-6603 (generic name: condoliase), an investigational product being studied for the treatment of radicular leg pain associated with lumbar disc herniation (LDH). The research, presented at the American Society of Pain and Neuroscience (ASPN) Annual Meeting, also included an analysis of healthcare resource utilization and costs associated with LDH surgery.

Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced the presentation of two analyses of data at the American Society of Pain and Neuroscience (ASPN) 2024 Annual Meeting, for SI-6603, an investigational therapy intended to treat radicular leg pain associated with lumbar disc herniation (LDH). The congress will take place July 11-24, 2024, in Miami, FL.

Ferring Pharmaceuticals, in partnership with Posterity Health, today launched a new Male Fertility program on Ferring’s Fertility Out Loud platform that empowers men to take the initiative to understand their fertility status. This new offering features a confidential, online assessment that provides their personal reproductive health insights after completion of a questionnaire as well as educational resources developed by Fellowship-trained Reproductive Urologists.

Ferring Pharmaceuticals today announced the final 60-month follow-up data from the Phase 3 study of ADSTILADRIN® (nadofaragene firadenovec-vncg) were presented at the American Urological Association (AUA) 2024 Annual Meeting. The study demonstrated an 80% overall survival rate and 49% cystectomy-free survival rate at Month 60 in adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1), and in patients with high-grade Ta/T1 without CIS. These data, which are the longest follow-up of efficacy and safety data reported for a novel agent for BCG-unresponsive NMIBC, were simultaneously published ahead of print and will be included in the July issue of The Journal of Urology®.

Ferring Pharmaceuticals and SK pharmteco today announced an agreement to scale up commercial manufacturing capacity for the drug substance of Ferring’s intravesical non-replicating gene therapy ADSTILADRIN (nadofaragene firadenovec-vncg) for ensuring long-term future supply. Following technology transfer, SK pharmteco, a contract development manufacturing organization (CDMO), will be qualified as another source for manufacturing, testing, and release of the medicine, subject to regulatory approval by the U.S. Food and Drug Administration (FDA).

Ferring Pharmaceuticals today announced start up of new studies in the United States (U.S.) for three new ADSTILADRIN in BLadder cancEr (ABLE) clinical trials in patients with non-muscle invasive bladder cancer (NMIBC) with plans to expand select clinical trials outside of the U.S. later this year. ADSTILADRIN was approved by the U.S. Food and Drug Administration (FDA) in December 2022 for adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors.

Ferring today published its 2023 Annual Report showing the company’s annual revenues were €2.2 billion, a decrease of -4% on the previous year at actual exchange rates (AER), but an increase of +1% at constant exchange rates (CER). EBITDA increased by +€43 million (+12% at AER) to reach €406 million and operating profit for the year reached €139 million.

Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced the presentation of data looking at the efficacy and safety profile of SI-6603 (generic name: condoliase), an investigational product intended to treat radicular leg pain associated with lumbar disc herniation (LDH). The research, presented at the American Society of Interventional Pain Physicians (ASIPP) Annual Meeting, included a registrational Phase 3 trial and an integrated safety analysis of six clinical studies, as well as a real-world analysis of current treatment options and gaps in clinical management of patients with newly-diagnosed LDH.

Ferring Pharmaceuticals today announced the presentation of three-year follow-up data from the Phase 3 study1 at the 39th Annual European Association of Urology (EAU) Congress demonstrating a sustained durable response of ADSTILADRIN (nadofaragene firadenovec-vncg) in two cohorts of adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). Follow-up data from the high-grade Ta/T1 papillary disease cohort were presented for the first time at the EAU meeting and interim data from the cohort of patients with carcinoma in situ (CIS) with or without papillary tumors were reported in November 2023. Results from both patient cohorts are available at clinicaltrials.gov/study/NCT02773849.

Ferring Pharmaceuticals announced today it is presenting the methodology for the ADSTILADRIN in BLadder cancEr (ABLE-41) Real World Evidence (RWE) study at the 20th Annual American Society of Clinical Oncologists Genitourinary Cancers Symposium (ASCO GU). ABLE-41 (NCT06026332) is an ongoing Phase 4 observational study evaluating the effectiveness, overall experiences, patterns of use, and safety of ADSTILADRIN® (nadofaragene firadenovec-vncg) in a U.S. real-world setting.

Ferring Pharmaceuticals today announced that ADSTILADRIN® (nadofaragene firadenovec-vncg) is now fully available across the U.S. for healthcare providers to prescribe for their adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Approved by the U.S. Food & Drug Administration (FDA) in December 2022, ADSTILADRIN is the first and only FDA-approved intravesical gene therapy for adults with NMIBC who no longer respond to standard therapy.

Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology.

Ferring Pharmaceuticals today announced the presentation of new 36-month follow-up data from the Phase 3 study at the 24th Annual Meeting of the Society of Urologic Oncology (SUO) demonstrating a sustained durability of response with ADSTILADRIN® (nadofaragene firadenovec-vncg) in adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1). ADSTILADRIN is the first and only intravesical gene therapy approved by the U.S. Food and Drug Administration (FDA) in this patient population.

Ferring Pharmaceuticals today announced two poster presentations at the American College of Gastroenterology’s (ACG) 2023 Annual Scientific Meeting for REBYOTA® (fecal microbiota, live – jslm), the first and only single-dose microbiome-based treatment approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.

Ferring Pharmaceuticals today announced four poster presentations at Infectious Disease Week (IDWeek) 2023 for REBYOTA® (fecal microbiota, live – jslm), the first and only single-dose microbiome-based treatment approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.

Ferring Pharmaceuticals today announced it will present two analyses of data for REBYOTA® (fecal microbiota, live – jslm), the first and only single-dose, FDA approved microbiome-based treatment to prevent recurrent Clostridioides difficile (C. diff) infection after antibiotic treatment. The data will be presented as part of the American College of Gastroenterology’s (ACG) 2023 Annual Scientific Meeting, being held October 20 – 25 in Vancouver, Canada.

Ferring Pharmaceuticals today announced it will present analyses of data for REBYOTA® (fecal microbiota, live – jslm), the first and only single-dose, FDA approved microbiome-based treatment to prevent recurrent Clostridioides difficile (C. diff) infection after antibiotic treatment, as part of Infectious Disease Week (IDWeek) 2023. The congress will take place in Boston, Mass., from October 11 to 15.

Ferring Pharmaceuticals today announced the first patient in the United States with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) was dosed with the commercially available intravesical gene therapy ADSTILADRIN® (nadofaragene firadenovec-vncg) as part of the ADSTILADRIN Early Experience Program announced earlier this year.

Royalty Pharma plc (Nasdaq: RPRX) and Ferring Pharmaceuticals today announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring’s Adstiladrin® (nadofaragene firadenovec-vncg) for up to US $500 million comprised of an upfront payment of US $300 million and a US $200 million milestone payment. The milestone payment is contingent on certain manufacturing goals that are expected to be achieved in 2025 for the FDA-approved intravesical gene therapy that Ferring will make available next month through an early experience program for the treatment of adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

Ferring Pharmaceuticals today announced that Therapeutic Advances in Gastroenterology has published an integrated safety analysis from five prospective clinical trials for REBYOTA® (fecal microbiota, live – jslm), the first and only single-dose, FDA approved microbiome-based treatment to prevent recurrent C. diff infection after antibiotic treatment. The analysis, which includes data from about 1,000 clinical trial participants, is the largest safety evaluation to date of any microbiota-based live biotherapeutic and includes safety data for up to two years.1

Ferring Pharmaceuticals announced today that Jean-Frédéric Paulsen has been appointed Executive Chairman of the Ferring Group, as it enters a new phase of growth following the approval of two innovative medicines by the US Food and Drug Administration.

Ad hoc announcement pursuant to Art. 53 LR

Ferring Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved a Prior-Approval Supplement (PAS) to the Biologics License Application (BLA) for the novel intravesical gene-therapy ADSTILADRIN® (nadofaragene firadenovec-vncg), enabling the Company to scale-up its drug substance manufacturing process at FinVector Oy located in Kuopio, Finland. Supplies from the scale-up process manufactured at FinVector’s FDA-approved facility will be available as part of the planned product launch.

Ferring Pharmaceuticals (Ferring) announced that its clinical development partner, Seikagaku Corporation (Seikagaku), achieved positive topline results for its registrational Phase 3 clinical trial of SI-6603, an investigational treatment for lumbar disc herniation (generic name: Condoliase).

Ferring Pharmaceuticals today announced three oral presentations and one poster presentation at Digestive Disease Week® (DDW 2023) for REBYOTA™ (fecal microbiota, live – jslm) a first-in-class single-dose microbiome-based treatment approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent C. difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.

Ferring Pharmaceuticals today announced that Open Forum Infectious Diseases has published a retrospective analysis of data evaluating the safety and efficacy of REBYOTA™ (fecal microbiota, live – jslm) for the prevention of recurrent Clostridioides difficile (C. diff) infection in a range of adult patients representative of those seen in clinical practice – including patients with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

Ferring Pharmaceuticals today announced it will present analyses of data for REBYOTA™ (fecal microbiota, live – jslm) at Digestive Disease Week® (DDW 2023). The congress will take place May 6-9, 2023, in Chicago, Ill. REBYOTA is the first microbiome-based treatment approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent C. difficile (C. diff) infection in adults, following antibiotic treatment for recurrent C. diff infection. REBYOTA is not indicated for the treatment of C. diff infection.

Ferring Pharmaceuticals and BioInnovation announce a new strategic collaboration to accelerate innovation in women’s health.

Today, an oral poster of the first post-authorisation Phase 4 real-world study, PROFILE, is being presented at the 13th Congress of the Pacific Society for Reproductive Medicine (PSRM) 2023 in Australia. The large, prospective, multi-national study confirms the effectiveness and safety of Rekovelle in routine clinical practice, with ongoing pregnancy rates similar to Phase 3 RCTs.1-3,5 The study was first published in Frontiers of Endocrinology in December 2022.5

Ferring Pharmaceuticals today announced that REBYOTA™ (fecal microbiota, live – jslm) is now available in the United States (U.S.). REBYOTA is the first and only microbiome-based treatment approved by the U.S. Food and Drug Administration (FDA) to prevent recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.

Ferring Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approved REBYOTA® (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.

Ferring Pharmaceuticals today announced the publication in the journal Drugs of its pivotal Phase 3 PUNCH™ CD3 clinical trial data, in which a single dose of RBX2660 demonstrated superiority to placebo as a treatment to reduce recurrence of Clostridioides difficile infection (CDI) after standard-of-care antibiotic treatment in a Bayesian analysis model. RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrent CDI (rCDI) after antibiotic treatment.

Ferring Pharmaceuticals today announced the presentation at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting of seven analyses for RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrent C. difficile infection (CDI) after antibiotic treatment.

Ferring Pharmaceuticals today announced the presentation of two subgroup analyses at Infectious Disease Week (IDWeek) 2022 that further characterize RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection (CDI) after antibiotic treatment.

Ferring Pharmaceuticals today announced it will present data from new analyses of RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection (CDI) after antibiotic treatment. The data will be presented as part of the American College of Gastroenterology’s Annual Scientific Meeting & Postgraduate Course (ACG) 2022. The congress will take place in Charlotte, North Carolina from October 21 to 26.

Ferring Pharmaceuticals today announced they will present analyses of RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection (CDI) after antibiotic treatment, as part of Infectious Disease Week (IDWeek) 2022. The congress will take place in Washington, D.C. from October 19 to 23.

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) issued a positive vote for RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection (CDI) after antibiotic treatment.

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) will hold a meeting on September 22, 2022, to review data supporting the biologics license application (BLA) for RBX2660, a microbiota-based live biotherapeutic studied for its potential to reduce recurrent C. difficile infection (CDI) after antibiotic treatment.

Ferring Pharmaceuticals today announced it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions.

Ferring Pharmaceuticals today announced the presentation of four abstracts at Digestive Disease Week (DDW) 2022 that further characterize RBX2660, a potential first-in-class microbiota-based live biotherapeutic studied to deliver a broad consortium of diverse microbes to the gut to reduce recurrent C. difficile infection (CDI) after antibiotic treatment.

Ferring Pharmaceuticals today announced they will present data from analyses of RBX2660, an investigational microbiota-based live biotherapeutic for reduction of recurrent C. difficile infection (CDI) after antibiotic treatment, as part of Digestive Disease Week (DDW 2022). The congress will take place in San Diego, CA, and virtually from May 21 – 24, 2022.

Forensic analysis of stone age human fertility to better understand why modern-day sperm counts are falling, and a project to support safe birth in rural Ethiopia by providing trained midwives and solar power kits, are among 17 winners of a new Ferring Pharmaceuticals grant programme unveiled today.

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced a publication detailing the development and validation of their first-of-its-kind prototype biomarker, designed to distinguish post-antibiotic disruptions to the human gut microbiota, known as dysbiosis, from healthy gut microbiota. The Microbiome Health Index for post-Antibiotic dysbiosis (MHI-A), published in Frontiers in Microbiology, was developed to better understand and manage the risks of antibiotic administration and help guide the development of live biotherapeutic products – a potential new class of drugs.1

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced the results of two key retrospective analyses at the American College of Gastroenterology 2021 annual congress. One analysis evaluated the safety and efficacy of investigational RBX2660 among a broad cohort of CDI patients with comorbidities commonly found in patients with CDI, and was recognized with a Presidential Poster Award for high-quality, novel, unique and interesting research.

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced they will present data from two new retrospective analyses as part of American College of Gastroenterology’s Annual Scientific Meeting & Postgraduate Course (ACG 2021). The congress will take place in Las Vegas from October 22 – 27, 2021.

Ferring Pharmaceuticals (US) today announced that it will be presenting four company-sponsored abstracts at the American Society for Reproductive Medicine (ASRM) 2021 Scientific Congress & Expo taking place October 17-20 in Baltimore, MD.

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced final results of an analysis from five prospective trials of its investigational microbiota-based live biotherapeutic, RBX2660, for the reduction of recurrent C. difficile infection (rCDI). The abstract, presented at IDWeek 2021, represents the first time these data are showcased together, and is one of only four abstracts to receive the Program Committee Choice award for outstanding scientific research.

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced they will present data from the clinical development program for RBX2660, an investigational microbiota-based live biotherapeutic for reduction of recurrent Clostridioides difficile (C. difficile) infection, as part of IDWeek 2021. The congress will take place virtually from September 29 – October 3, 2021.

After nearly a decade of public-private collaboration, Ferring Pharmaceuticals today announces the first use of heat-stable carbetocin (Carbetocin Ferring) for the prevention of excessive bleeding after birth, known as postpartum haemorrhage (PPH). Heat-stable carbetocin is now available for use in healthcare facilities across India, in the prevention of excessive bleeding following vaginal and caesarean section births.

Ferring Pharmaceuticals announced today that Frederik Paulsen is stepping down from his role as Chairman of the Board of Directors* and transitioning to the role of Honorary Chairman. Lars Rebien Sørensen is appointed Chairman of the Board of Directors. Jean-Frédéric Paulsen is also appointed to the Board of Directors. All of these changes are effective immediately.

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, announced today the first presentation of interim data from a Phase 3 open-label study showing strong trends in efficacy and safety for investigational microbiota-based live biotherapeutic RBX2660 in reducing recurrent Clostridioides difficile (C. difficile) infection over six months, consistent with previous findings in the comprehensive RBX2660 clinical development program. The study also enrolled patients diagnosed with co-morbid conditions such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). The patients enrolled closely reflect the recurrent C. difficile infection patients who healthcare providers treat every day. The results were presented at Digestive Disease Week® (DDW) 2021, taking place virtually this year from May 21-23.

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH™ CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing recurrence of Clostridioides difficile infection (CDI) over placebo. RBX2660 is an investigational, potential first-in-class microbiota-based live biotherapeutic.

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced that Phase 3 data evaluating its investigational microbiota-based live biotherapeutic RBX2660 for reduction of recurrent Clostridioides difficile (C. difficile) infection will be presented as part of an invited talk at Digestive Disease Week® (DDW) 2021. The congress will take place virtually from May 21-23, 2021.